Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Ain Shams University

Status

Completed

Conditions

Non Alcoholic Fatty Liver Disease

Treatments

Diagnostic Test: plasma pentraxin-3

Study type

Observational

Funder types

Other

Identifiers

NCT03276039

456

Details and patient eligibility

About

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

Enrollment

70 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients with NAFLD.
Patients with NAFLD and chronic hepatitis C viral infection.

Exclusion criteria

Current or past consumption of significant amount of alcohol more than 21 drinks and 14 drinks per week for men and women respectively.
Patients receiving Drugs which cause fatty liver as amiodarone, diliazem, tamoxifen, steroids.
Patients who take statins as it has lowering effect on plasma PTX3.
Patients having any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, elevated serum bilirubin level to more than two folds the upper limit of normal.
Patients with heart failure.
Patients with autoimmune rheumatic disease.
Patients with chronic kidney diseases.
Patients with sepsis.